This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nair, A P Articles by Moroni, C Search for Related Content PubMed PubMed Citation Articles by Nair, A P Articles by Moroni, C

 Previous Article  |  Next Article 

Mol Cell Biol. 1989 March; 9(3): 1183-1190

A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production.

Friedrich Miescher-Institut, Basel, Switzerland.

ABSTRACT

Autocrine interleukin 3 (IL-3)-secreting tumors were generated from an IL-3-dependent mouse mast cell line (PB-3c) after introduction of the v-H-ras oncogene. Tumor progression was characterized by four distinct phenotypes. The first corresponded to immortalized mast cells unresponsive to the oncogenic effect of v-H-ras. The second was expressed in a clonable subpopulation of PB-3c cells and was marked by the competence to form v-H-ras-dependent tumors (immortalized transformation competence). The third was a direct effect of v-H-ras expression on all PB-3c cells and was characterized in vitro by a reduced IL-3 requirement. Upon injection of v-H-ras-expressing, transformation-competent cells into mice, the final, fully malignant phenotype developed with a long latency period and was marked in vitro by independence of exogenous IL-3 and by autocrine IL-3 stimulation. Northern (RNA) blot analysis and an RNase A-T1 protection assay showed that IL-3 production was strictly associated with the tumor phenotype. Two of six tumors showed an alteration at the 5' region of the IL-3 gene. We conclude that v-H-ras required complementation by IL-3 gene rearrangement or an alternate event to generate autocrine mastocytomas.

This article has been cited by other articles:

• Stoecklin, G., Lu, M., Rattenbacher, B., Moroni, C. (2003). A Constitutive Decay Element Promotes Tumor Necrosis Factor Alpha mRNA Degradation via an AU-Rich Element-Independent Pathway. Mol. Cell. Biol. 23: 3506-3515 [Abstract] [Full Text]  
• Stoecklin, G., Ming, X.-F., Looser, R., Moroni, C. (2000). Somatic mRNA Turnover Mutants Implicate Tristetraprolin in the Interleukin-3 mRNA Degradation Pathway. Mol. Cell. Biol. 20: 3753-3763 [Abstract] [Full Text]  
• Bilsborough, J., Van Pel, A., Uyttenhove, C., Boon, T., Van den Eynde, B. J. (1999). Identification of a Second Major Tumor-Specific Antigen Recognized by CTLs on Mouse Mastocytoma P815. J. Immunol. 162: 3534-3540 [Abstract] [Full Text]  
• Nair, A. P. K., Hirsch, H. H., Colombi, M., Moroni, C. (1999). Cyclosporin A Promotes Translational Silencing of Autocrine Interleukin-3 via Ribosome-Associated Deadenylation. Mol. Cell. Biol. 19: 889-898 [Abstract] [Full Text]  
• Hirsch, H. H., Nair, A. P. K., Backenstoss, V., Moroni, C. (1995). Interleukin-3 mRNA Stabilization by a trans-Acting Mechanism in Autocrine Tumors Lacking Interleukin-3 Gene Rearrangements. J. Biol. Chem. 270: 20629-20635 [Abstract] [Full Text]